Active — Not RecruitingNot Applicable

Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

Denmark144 participantsStarted 2023-10-01

Plain-language summary

PURPOSE: To investigate the effect of the disease and HSCT on muscle dysfunction and to investigate the prognostic role of muscle dysfunction at critical decision points in patients with hematological diseases referred to hematopoietic stem cell transplant (HSCT). HSCT: Patients diagnosed with malignant hematological diseases who are referred to myeloablative HSCT, to a myeloablative "reduced toxicity conditioning" regime with Fludarabine and Treosulfane (FluTreo) or to non-myeloablative HSCT.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with acute myelogenous leukaemia (AML), acute lymphatic leukaemia (ALL), chronic myelomonocytic leukaemia (CMML), myelodysplastic syndrome (MDS), chronic lymphatic leukaemia (CLL), malignant lymphomas or multiple myeloma (MM) referred to myeloablative HSCT, myeloablative RTC-HSCT or non-myeloablative HSCT at the Department of Haematology, Rigshospitalet, Blegdamsvej. Exclusion Criteria: * age \<18; pregnancy; physical or mental disabilities precluding test of muscle function; inability to read and understand Danish

What they're measuring

Cohort 1 and Cohort 2 Medical treatment complications

Timeframe: From baseline to 1 year follow-up

Trial details

NCT IDNCT04167683

SponsorRigshospitalet, Denmark

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-01

View on ClinicalTrials.gov More Hematologic Diseases trials